The estimated Net Worth of Scott E. Royer is at least $257 Tysiąc dollars as of 3 September 2020. Mr Royer owns over 500 units of Vaccinex Inc stock worth over $25,509 and over the last 6 years he sold VCNX stock worth over $0. In addition, he makes $231,701 as Chief Financial Officer at Vaccinex Inc.
Mr has made over 2 trades of the Vaccinex Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 500 units of VCNX stock worth $1,950 on 3 September 2020.
The largest trade he's ever made was buying 2,000 units of Vaccinex Inc stock on 6 February 2019 worth over $9,960. On average, Mr trades about 357 units every 82 days since 2019. As of 3 September 2020 he still owns at least 4,499 units of Vaccinex Inc stock.
You can see the complete history of Mr Royer stock trades at the bottom of the page.
Scott E. Royer C.F.A., M.B.A. is the Chief Financial Officer at Vaccinex Inc.
As the Chief Financial Officer of Vaccinex Inc, the total compensation of Mr A at Vaccinex Inc is $231,701. There are 2 executives at Vaccinex Inc getting paid more, with Dr. Maurice Zauderer Ph.D. having the highest compensation of $357,265.
Mr A is 47, he's been the Chief Financial Officer of Vaccinex Inc since . There are 6 older and no younger executives at Vaccinex Inc. The oldest executive at Vaccinex Inc is John E. Leonard Ph.D., 75, who is the Sr. VP of Devel..
Scott's mailing address filed with the SEC is C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER, NY, 14620.
Over the last 6 years, insiders at Vaccinex Inc have traded over $3,161 worth of Vaccinex Inc stock and bought 14,062,785 units worth $29,583,294 . The most active insiders traders include Albertfcmi Parent Co. Fried..., Maurice Zauderer oraz Maurice Vaccinex (Rochester.... On average, Vaccinex Inc executives and independent directors trade stock every 61 days with the average trade being worth of $2,417,268. The most recent stock trade was executed by Albertfcmi Parent Co. Fried... on 9 August 2024, trading 100 units of VCNX stock currently worth $451.
located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop
Vaccinex Inc executives and other stock owners filed with the SEC include: